Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.Methods: Adults with psoriasis initiating guselkumab, se...

詳細記述

書誌詳細

出版年:	Journal of Dermatological Treatment
主要な著者:	Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven R. Feldman
フォーマット:	論文
言語:	英語
出版事項:	Taylor & Francis Group 2024-12-01
主題:	Psoriasis biologics guselkumab treatment discontinuation persistence remission
オンライン･アクセス:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2349658